The omicron subvariants BA.1 and BA.2 of SARS-CoV-2 have dominated the COVID-19 pandemic in early 2022. In many countries, these viruses are now outcompeted by emerging subvariants, with BA.5 being responsible for the current ...
Jul 1, 2022
0
149
Cancer cases and deaths are expected to double in Africa during the next two decades, according to findings from a new study by Penn State College of Medicine researchers. The study also reveals that the region lacks sufficient ...
Jun 14, 2022
0
46
Vaccines based on inactivated SARS-CoV-2 virus are commonly used in developing countries due to their low cost. New research from Karolinska Institutet in Sweden shows that a booster shot of mRNA vaccine to individuals who ...
May 13, 2022
0
61
The SARS-CoV-2 omicron variant's "milder" outcomes are likely due to more population immunity rather than the virus' properties, according to a paper by William Hanage, associate professor of epidemiology at Harvard T.H. ...
Feb 3, 2022
7
268
A sub-variant of the highly contagious Omicron coronavirus strain is even more infectious than the original version, according to a Danish study published on Monday.
Jan 31, 2022
0
278
The omicron variant of SARS-CoV-2 diverged from previous SARS-CoV-2 variants as a result of adaptive evolution, in which beneficial mutations are passed on to future generations through natural selection, rather than through ...
Jan 26, 2022
0
333
Three studies released Friday offered more evidence that COVID-19 vaccines are standing up to the omicron variant, at least among people who received booster shots.
Jan 21, 2022
0
197
A preliminary US study of nearly 70,000 COVID positive people showed a substantially reduced risk of hospitalization and death from Omicron even after controlling for growing population immunity levels.
Jan 12, 2022
0
299
The Omicron variant was detected for the first time in South Africa in November 2021 and has since spread to many countries. It is expected to become the dominant variant within a few weeks or months. Initial epidemiological ...
Jan 7, 2022
2
528
A booster of US coronavirus vaccine Johnson & Johnson was 85 percent effective in preventing serious illness in areas where Omicron was dominant, a South African trial study indicated Thursday.
Dec 30, 2021
0
223
